Evidence map›Paper›PMID 35774682›Full record

ReviewCureus2022

Biliary Duct Hamartomas: A Systematic Review.

Abdul Ahad E Sheikh, Anthony P Nguyen, Katarina Leyba, Nismat Javed, Sana Shah, Alexander Deradke, Christopher Cormier, Rahul Shekhar, Abu Baker Sheikh

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Abdul Ahad E SheikhInternal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Anthony P NguyenInternal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
Katarina LeybaInternal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
Nismat JavedInternal Medicine, Shifa International Hospital, Islamabad, PAK.
Sana ShahMedicine, Aga Khan University, Karachi, PAK.
Alexander DeradkeInternal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
Christopher CormierPathology, University of New Mexico School of Medicine, Albuquerque, USA.
Rahul ShekharInternal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
Abu Baker SheikhInternal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
Shifa International Hospital · PKAga Khan University · PKThe Wright Center for Graduate Medical Education · USUniversity of New Mexico · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary duct hamartomas are benign intrahepatic bile duct lesions. Despite being primarily incidental findings on imaging, these lesions can provide a diagnostic conundrum due to their shared characteristics with malignant tumors. The goal of this systematic review is to offer a thorough clinical profile of biliary duct hamartomas. There were 139 cases of biliary duct hamartomas identified in a structured systematic review of the literature. Patient demographics, clinical presentation, significant laboratory and imaging data, diagnostic modalities, treatment choices, and outcomes were all studied and reported. Biliary duct hamartomas present with mild symptoms and laboratory abnormalities, and while being visible on imaging, the results are non-specific and may require biopsy in case of red flag signs such as weight loss and a progressive increase in the size of the lesion. Furthermore, there are currently no published guidelines for the treatment of biliary duct hamartomas, and many people have had surgery despite the clinically benign nature of these abnormalities. As per the findings of the study, individuals who exhibit signs of malignancy should be investigated further. Eyeballing for red flag symptoms, followed by a specialized imaging scan and invasive treatment, is the three-step approach to biliary duct hamartomas. Since our recommendations include a shift in strategy and do not contradict existing rules, there are likely to be few roadblocks to improvement; the key barriers being technological equipment and image quality. In this study, we intended to pave the way for future research in the field. In our opinion, the next decade will bring a better understanding of the characteristics of biliary hamartomas, disease symptoms, and better recognition of any suspicious features. These indications will aid in reducing the number of unneeded surgical or invasive operations. Finally, the findings of these future studies will allow the medical community to improve and provide the best care possible.

Indexed as

biliary duct hamartomasbiliary hamartomasmultiple biliary duct hamartomasmultiple biliary hamartomasvon meyenburg complexes

Identifiers

PMID35774682
PMCPMC9236677
OpenAlexW4281564166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.